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Tumor Doubling Time of Pulmonary
Carcinoid Tumor Measured by CT
Douglas H Russ, BS, Julie A Barta, MD, Nathaniel R Evans, MD,
Robert T Stapp, DO, Gregory C. Kane, MD*

Background
• Pulmonary Carcinoid Tumor (PCT) is a neuroendocrine neoplasm
• 1-2% of all lung cancers
• Typical (low grade) and atypical
(intermediate grade) subtypes
• Metastatic, but indolent
– Clinically known to grow slowly, but limited literature on
growth rates

• Often identified as solitary nodules on incidental
radiography (e.g. CXR, Chest CT)
Phillipe Joubert, MD, PhD

Background
• What to do once incidental nodule is identified?

• If PCT is truly slow-growing, is a 2-year follow up
timeframe long enough to detect tumor growth on CT?

MR, 78 y.o. male
Chest CT for Hx of bronchiectasis
→ incidental 5 mm peripheral
nodule visible

Nodule now measures 9 mm

01-2009
11-2007

09-2017
12-2016

Repeat CT → nodule now 6 mm

Percutaneous needle
biopsy of nodule now
measuring 10 mm

Objectives
& Hypothesis
• Research Question
– What is the true growth rate of PCT as measured on CT?

• Hypothesis
– We hypothesized that PCT would demonstrate a prolonged tumor doubling time compared to
other lung neoplasms.

Approach
• Retrospective medical chart review
• Medical charts (EPIC) & radiographic scans (PACS)
• PCT nodule dimensions measured manually or retrieved from radiology reports
• Inclusion criteria
– Pathologic diagnosis of PCT
– ≥ 2 years of radiographic follow up by CT prior to biopsy/resection
– Tumor demonstrated definitive growth*

• 14/89 patients with pathologically-confirmed PCT met all criteria
• 11 typical carcinoids, 3 atypical carcinoids
*defined as an increase in average nodule diameter ≥ 2 mm1

Results: Tumor Doubling Time
Volume Doubling Time1 = [ln2 × ∆T] / [ln(V2/V1)] = ∆T / [log2(V2/V1)]
Patient MR → 171 weeks

11 typical PCTs demonstrated definitive growth
Median DT = 140 weeks
Mean DT = 161 ± 105
SCLC2 → 6 weeks
SCC2 → 13 weeks
Adenocarcinoma2 → 20 weeks (solid), 36 weeks (subsolid)

Conclusions
•

The median doubling time of typical PCT was 141 weeks, or almost three years.

● The frequency of atypical carcinoids was too small to form any conclusion
about growth rates.
● It is conceivable that typical PCTs detected early with small diameter may be
mistaken for benign non-growing lesions when followed for less than two years
in low-risk patients.

Future Directions
•

Analysis of larger, prospective cohorts could identify the frequency of PCT and
other tumors with prolonged doubling time compared with non-neoplastic lung
nodules.
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